Engflag
Advertisements

Colchicine 1mg

Quick links to important sections

Colchicine 1mg

Colchicine 1mg_DE
Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Colchicine 1mg

Quick Facts

Property Description
Active ingredient Colchicine
Form Tablet (Oral)
Pharmacological class Antimitotic agent, Microtubule inhibitor
General purpose Management of acute inflammatory crises (e.g., gout flares)
Origin Naturally derived alkaloid (from Colchicum autumnale)

Identity and Origin

Colchicine 1mg is a single-ingredient oral medication presented as a tablet containing the active compound colchicine. This substance is chemically defined as a tricyclic alkaloid. The medication's identity as a prescription drug (Rx) differentiates it from over-the-counter options, underscoring the requirement for medical supervision due to its narrow therapeutic index.

The medication is historically derived from the autumn crocus plant (Colchicum autumnale), making it a naturally sourced compound, though it is prepared synthetically for pharmaceutical quality and consistency. The designation of 1mg refers to the precise, measured quantity of the active ingredient contained within each tablet for oral administration.

Pharmacological Class and Function

Colchicine is categorized as an antimitotic agent and, more specifically, a microtubule inhibitor. This classification identifies it as a specialized medication that operates at the cellular level. Its cellular interference mechanism is utilized for suppressing the inflammatory processes characteristic of crystal-induced diseases.

Its mechanism involves interfering with the internal structures of cells—the microtubules—which restricts the mobility of certain inflammatory cells (leukocytes) within the body. This specific action separates it from conventional anti-inflammatory medications, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), positioning colchicine as a selective tool for managing acute cellular inflammatory responses.

General Purpose

The general therapeutic purpose of Colchicine 1mg is the management and control of acute, severe inflammatory episodes. It is primarily utilized for conditions where its distinct anti-inflammatory cellular mechanism is required.

By interrupting the inflammatory cascade, the medication's objective is to provide relief from the sudden, intense pain, swelling, and redness associated with specific crises, such as flares caused by crystal deposition like gout, or symptoms related to inherited disorders like Familial Mediterranean Fever (FMF). It is reserved for these specialized inflammatory contexts.

Regulatory References

  1. Colchicine - Mechanism of Action
Advertisements

What side effects are possible with Colchicine 1mg?

Colchicine has a narrow therapeutic window and is considered a potentially toxic medication; the prescribed dose must not be exceeded. The drug's safety profile is defined by its potential for severe toxicity, especially with higher doses, long-term use, or in the presence of certain patient risk factors.

Adverse Reactions

Frequency System Organ Class Key Adverse Reactions
Common Gastrointestinal Nausea, vomiting, abdominal pain, diarrhea. These symptoms are often the first sign of toxicity and warrant immediate discontinuation.
Not Known Blood and Lymphatic System Severe bone marrow depression (e.g., agranulocytosis, aplastic anemia, thrombocytopenia) and blood cell dyscrasias.
Not Known Musculoskeletal and Connective Tissue Myopathy (muscle weakness/pain) and rhabdomyolysis (severe muscle breakdown).
Not Known Nervous System Peripheral neuritis/neuropathy.

Safety Considerations and Restrictions

Serious Adverse Reactions: The most serious risks include fatal overdose, severe blood dyscrasias (which can be sudden and life-threatening), and neuromuscular toxicity (myopathy/rhabdomyolysis) which may lead to kidney damage.

Contraindications and Drug Interactions: Colchicine is strictly contraindicated in patients with severe renal or hepatic impairment. It is also contraindicated in patients with impaired renal or hepatic function who are concurrently taking a P-glycoprotein (P-gp) inhibitor or a strong CYP3A4 inhibitor (due to the risk of fatal toxicity). The drug is contraindicated in pregnancy and in women who are breastfeeding.

Safety Monitoring: Due to the risk of blood dyscrasias, regular monitoring of the complete blood picture is essential, particularly during long-term treatment. Caution is advised for elderly, debilitated patients, and those with pre-existing cardiac or gastrointestinal conditions, as they may be more susceptible to cumulative toxicity.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documentation classifies colchicine as extremely toxic in overdose, with reports of fatal outcomes in both adults and children. The drug has a narrow therapeutic window, and all suspected ingestions require immediate medical assessment.

Overdose presents a two-phase toxicity pattern. Initial signs (onset 2 to 12 hours) include severe gastrointestinal symptoms: nausea, vomiting, abdominal pain, and hemorrhagic diarrhea. This is followed by a high risk of delayed multisystem organ failure (24 to 72 hours).

Documented Severe Outcomes

System Affected Severe Manifestations
Hematologic Myelosuppression, pancytopenia, aplastic anemia
Cardiovascular Myocardial depression, cardiac arrhythmias
General Acute renal failure, hepatic damage, rhabdomyolysis

Immediate hospitalization is mandatory for continuous monitoring and supportive care. No specific antidote is known for colchicine toxicity. Management is strictly symptomatic and supportive, including the potential use of oral activated charcoal. Neither hemodialysis nor haemoperfusion effectively removes the drug.

Patients with renal or hepatic impairment and those at the extremes of age face a documented increased risk of severe toxicity and fatality. Life-threatening toxicity can also result from co-ingestion with strong CYP3A4 and/or P-gp inhibitors.

Advertisements

Therapeutic Uses of Colchicine 1mg

What Colchicine 1mg Treats: Main Uses and Benefits

Colchicine 1mg is commonly used to help with symptoms related to physical discomfort across several therapeutic domains. The medication is generally considered relevant in conditions characterized by periods of heightened symptoms. It is applied in addressing the systemic imbalance related to inflammatory states and may be considered relevant in the management of: acute gout flare-ups, the prevention of recurrent gout and pericarditis, and the long-term control of Familial Mediterranean Fever (FMF).

In clinical settings that involve acute or unstable symptom patterns, Colchicine is commonly used to help with symptoms related to heightened physiological activity, especially those linked to the sudden, severe joint pain and swelling. It supports patients during episodes of heightened discomfort, contributing to easing the overall symptom load.

“It plays a role in managing symptom clusters that may become intense or disruptive, especially those linked to recurrent, systemic inflammatory processes.”

For chronic conditions like FMF, it is commonly used to help with the recurrent episodes of fever and serosal inflammation, which may assist with maintaining functional stability during symptomatic periods for both adults and children 4 years of age and older. Furthermore, in patients with established cardiovascular risk, it may be part of symptomatic management to help manage the systemic imbalance related to inflammatory states.

Quick Fact: Support for Acute Inflammation
Primary Focus Acute Localized Inflammatory Pain (gout flare-ups)
Long-term Symptomatic Support Prophylaxis against recurrent episodes and systemic inflammation.
Patient Support Supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility to use Colchicine 1mg is strictly defined by regulatory criteria concerning a patient’s organ function, age, and concurrent health status due to the drug’s narrow therapeutic index.

Category Official Regulatory Statement
Populations for whom use is allowed Adults are eligible for approved uses. Children 4 years of age and older are eligible for Familial Mediterranean Fever (FMF).
Populations for whom use is contraindicated Patients with pre-existing blood dyscrasias or known hypersensitivity. Use is strictly prohibited in patients with renal or hepatic impairment who are concurrently taking specific strong P-gp or CYP3A4 inhibitors.
Age-related eligibility rules Pediatric use for gout is not recommended. Older adults (Geriatric) are considered a high-risk group requiring enhanced monitoring due to increased susceptibility to toxicity.
Pregnancy and lactation eligibility status Pregnancy is conditional upon a formal risk assessment; some regions list it as contraindicated. Lactation requires caution as the drug is excreted into breast milk.
Eligibility-related restrictions Severe renal or hepatic impairment mandates close monitoring and modification of the standard dose. Males of reproductive potential are advised of a rare, transient risk to fertility.

Eligibility Classifications (High-Level)

Eligibility is classified as Contraindicated (absolute prohibition), Restricted (conditional use with modification), or Eligible (approved use in specific age groups). The regulatory basis for these constraints is the high risk of systemic toxicity, particularly when the body's clearance mechanisms are compromised.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of colchicine is defined by its clearance through the CYP3A4 metabolic enzyme and the P-glycoprotein (P-gp) efflux transporter, as noted in regulatory prescribing information.

Pharmacokinetic Restrictions

Co-administration with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) or P-gp inhibitors (e.g., cyclosporine, ranolazine) is documented to cause a significant increase in colchicine plasma concentrations. This pharmacokinetic interaction is formally classified as contraindicated in patients with pre-existing renal impairment or hepatic impairment due to the associated risk of serious toxicity. Moderate inhibitors of these pathways may also require caution.

Pharmacodynamic and Substance Interactions

Interaction Type Interacting Substance(s) Official Outcome/Restriction
Drug-Drug Statins (e.g., simvastatin) and Fibrates (e.g., fenofibrate) Increased risk of myopathy and rhabdomyolysis (additive pharmacodynamic effect).
Drug-Food Grapefruit or Grapefruit Juice Must be avoided due to inhibition of CYP3A4, which increases colchicine exposure.
Drug-Supplement Cyanocobalamin (Vitamin B12) May cause reversible malabsorption by altering the intestinal mucosa.

These restrictions underscore the narrow therapeutic window of the medication, where inhibition of clearance can lead to systemic accumulation.

Advertisements

Mechanism of Action

Disruption of Cellular Microtubules and Movement

Colchicine works at the molecular level by binding to the protein beta-tubulin, preventing its assembly into microtubules. This primary action interferes with the microtubule-dependent processes of immune cells, such as neutrophils, inhibiting their capacity for organized movement and migration. This mechanism results in an inhibition of neutrophil migration and accumulation at the inflammatory focus.

️ Suppression of NLRP3 Inflammasome Activation

The molecule also engages a significant intracellular pathway by interfering with the assembly of the NLRP3 inflammasome complex. By suppressing this specific signaling pathway, the drug prevents the subsequent activation of Caspase-1, which is the enzyme responsible for processing and releasing large amounts of the pro-inflammatory cytokine Interleukin-1beta (IL-1beta).

Physiological Dampening of Acute Inflammation

The physiological effect is the result of these two coordinated cellular actions—the physical arrest of migrating cells and the chemical suppression of inflammatory signaling. This dual mechanism modulates the inflammatory cascade by limiting the immune cell's capacity to escalate the localized response, influencing the physiological progression of the acute process.

Advertisements

Dosage and Administration Information

How Colchicine 1mg is Used: Official Administration Guidelines

Colchicine is administered exclusively via the oral route, typically as a tablet, capsule, or oral solution. Official instructions establish two distinct usage protocols based on the clinical context: a specific short course for acute episodes and a long-term daily regimen for preventative treatment.

Administration Protocols

Usage Context Official Dosing Regimen (Examples) Procedural Restrictions
Acute Flare Management Initial dose of 1.2 mg (e.g., two 0.6 mg tablets), followed by 0.6 mg one hour later. Maximum total dose of 1.8 mg over the first hour. Must be started at the first sign of a flare; the course must not be repeated for at least 3 days (72 hours).
Chronic Prophylaxis/FMF 0.6 mg once daily or in one to two divided doses. Adult FMF doses range from 1.2 mg to 2.4 mg daily. Administered without regard to meals; constitutes long-term therapy.

Use Protocol Structure

The official dosing schedule governs both the precise quantities and the mandatory timing intervals for administration. For acute flares, the administration is strictly time-critical, requiring the two-dose sequence to be completed promptly to adhere to the labeled use. In contrast, use for prophylaxis and Familial Mediterranean Fever (FMF) involves a continuous, daily frequency pattern. These protocols also require population-specific adjustments: for example, patients with severe kidney impairment have a substantially reduced total recommended acute dose of a single 0.6 mg dose. The regular prophylactic dose should only be resumed 12 hours after the acute dose is fully completed.

Advertisements

Recent Clinical Evidence

Colchicine 1mg: Recent Clinical Evidence

Evidence for use in Acute Gout Flare Treatment

Colchicine 1mg was studied for use in conditions characterized by acute or disruptive episodes like a gout flare. Research utilized short-term randomized controlled trials (RCTs) during periods of increased symptom activity. These studies explored how symptoms change over defined time intervals, with researchers monitoring outcomes related to physical discomfort and measurements of joint swelling. The populations studied were typically adults experiencing a new or recurrent flare.

The trials documented findings related to changes measured in patient-reported outcomes describing perceived discomfort. Studies monitored the incidence of side effects like nausea and diarrhea; reports described that these patterns appeared related to the specific dosage regimen that was used.

Evidence for use in Gout Flare Prophylaxis

Colchicine 1mg was studied for use during the initiation of urate-lowering therapy, a research scenario involving conditions characterized by fluctuating or episodic manifestations. Research utilized both RCTs and longer-term observational cohorts to evaluate its application. These studies monitored outcomes describing episodic or acute changes, specifically focusing on the frequency and number of acute gout flare-ups. The studies involved adult patients with chronic gout beginning a new treatment aimed at reducing uric acid levels.

What is Still Uncertain About Colchicine 1mg Research

Evidence is limited when it comes to long-term follow-up; research exploring symptom changes after the immediate acute phase is generally scarce. These short-term study results apply only to the populations studied under the specific conditions of the trials.

There is a consistent need for more dedicated research in specific patient groups, as data for certain groups remain insufficient. Studies indicate that data for certain groups, such as those with significant kidney or liver issues, are limited, as these patients were often excluded from the original controlled studies. Questions surrounding the long-term effects are not fully established.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Colchicine 1mg (FAQ)

Q: What is Colchicine 1mg typically used for?

A: Colchicine is a medication indicated for treating acute gout flares and for the prophylaxis (prevention) of gout flares. It is also sometimes used to treat Familial Mediterranean Fever (FMF).

Q: How does Colchicine work?

A: Research suggests that Colchicine may work by interfering with certain inflammatory processes. It is understood to reduce inflammation associated with gout flares.

Q: What are common side effects associated with Colchicine 1mg?

A: The most frequently reported adverse effects are related to the gastrointestinal system and include diarrhea, nausea, vomiting, and abdominal pain. Other reported effects may include blood disorders and muscle problems.

Q: Is Colchicine 1mg considered safe for everyone?

A: Colchicine is generally not recommended for individuals with serious kidney or liver impairment. It may also interact with many other medications, which can increase the risk of adverse effects. Healthcare providers review individual health profiles to assess appropriateness.

Advertisements

How should Colchicine 1mg be stored and disposed of?

How to Store and Dispose of Colchicine 1mg

Official labeling defines strict conditions for storing and discarding Colchicine 1mg tablets to ensure product integrity and public safety.

Required Storage Conditions

Colchicine 1mg must be stored at Controlled Room Temperature, which is maintained between 20°C and 25°C (68°F and 77°F). The tablets must be protected from light and moisture. To maintain stability, the medication must be kept in the original container and sealed tightly closed.

Requirement Specific Regulatory Instruction
Temperature Controlled Room Temperature: 20°C – 25°C
Protection Keep tightly closed; protect from light and moisture
Child Safety Keep out of the reach and sight of children

Disposal Instructions

Unused or expired Colchicine must be disposed of according to local regulations. This medication should not be discarded via wastewater (flushed down a toilet) or standard household trash. Patients are advised to utilize official drug take-back programs or consult a pharmacist for guidance on regulatory disposal protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Colchicine 1mg found in:

A-Z Index: